SCHEMBL2255676

SCHEMBL2255676

CC(C)(C)OC(=O)N1CCc2ccc(Cl)c(C(N)c3ccccn3)c2CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.45
POLB P06746 1/20 0.44
GRM5 P41594 2/20 0.42
ESR2 Q92731 1/20 0.41
NR1H2 P55055 1/20 0.41
GRM1 Q13255 1/20 0.39
MAPT P10636 1/20 0.38
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
MAPK1 P28482 1/20 0.36
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
USP30 Q70CQ3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2254143 0.87 GPR119 (0.43) GPR119POLBGRM5ESR2NR1H2
SCHEMBL2252816 0.78 ESR2 (0.50) GPR119POLBESR2NR1H2MAPT
SCHEMBL506191 0.76 ESR2 (0.47) GPR119POLBGRM5ESR2NR1H2
SCHEMBL2251834 0.76 ESR2 (0.43) GPR119POLBESR2NR1H2MAPT
SCHEMBL10228372 0.75 NR1H2 (0.55) GPR119POLBESR2NR1H2MAPT
SCHEMBL2255679 0.75 ACHE (0.46) GPR119POLBGRM5ESR2NR1H2
SCHEMBL2254144 0.74 POLB (0.42) GPR119POLBGRM5ESR2NR1H2
SCHEMBL506203 0.73 ESR2 (0.57) GPR119POLBESR2NR1H2MAPT
SCHEMBL2255439 0.73 POLB (0.40) GPR119POLBGRM5ESR2NR1H2
SCHEMBL14115666 0.73 ESR2 (0.49) GPR119POLBESR2NR1H2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994163-B2 e.g. 3-tert-Butoxycarbonyl-7-chloro-6-chloromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; serotonin receptor agonist; antidepressant, anxiolytic agent; obesity, obsessive compulsive disorder ELI LILLY AND COMPANY (US) 2011-08-09 US disclosed
EP-1924560-B1 6-SUBSTITUTED- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2009-08-05 EP disclosed
US-20080255092-A1 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists ELI LILLY AND COMPANY 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255092-A1 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists HTR2C, HTR3C, HTR3A GPR119 38/4885POLB 4614/4885GRM5 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.